Entolimod

Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm

Retrieved on: 
Tuesday, June 14, 2022
Certified Public Accountant, Fibromyalgia, Company, Income, Cancer, Pancreatic cancer, Autoimmunity, Budget, GLOBE, Patient, TLR9, COVID-19, Antibody, NASDAQ, SEC, TLR5, Virus, Multiple sclerosis, Homeostasis, TLR, Entolimod, TLR4, Bookkeeping, Vaccine

Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis.

Key Points: 
  • Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis.
  • Statera Biopharma has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .
  • We have based these forward-looking statements on the current expectations about future events held by management.
  • The forward-looking statements included in this press release are made only as of the date hereof.

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing

Retrieved on: 
Monday, May 23, 2022
Cancer, Company, Autoimmunity, Cleveland BioLabs, TLR, Exercise, Patient, Homeostasis, Cleveland, Antibody, Coronavirus, TLR5, Therapy, COVID-19, Fibromyalgia, Research, Entolimod, TLR4, Compliance, Virus, Multiple sclerosis, Budget, Union, Risk, Calendar, Pancreatic cancer, SEC, Growth, TLR9, Letter, Annual report, GLOBE, Online gambling, Nasdaq

In addition, the Company has the potential to reinvirogate its pipeline with certain assets from Lay Sciences, Inc. as previously announced.

Key Points: 
  • In addition, the Company has the potential to reinvirogate its pipeline with certain assets from Lay Sciences, Inc. as previously announced.
  • On April 19, 2022, the Company received notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Annual Report on Form 10-K for the period ending December 31, 2021.
  • In a subsequent letter dated May 18, 2022 the Company received further notification from Nasdaq that it had failed to comply with Nasdaq Listing Rule 5250(c)(1) because it was delinquent in filing its Quarterly Report on Form 10-Q for the three-month period ending March 31, 2022.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

Retrieved on: 
Tuesday, May 17, 2022
Cancer, Megaphone, Association of American Universities, Breast, Humanities, Engineering, Company, Assistant, U.S. Securities and Exchange Commission, Breast cancer, Exercise, Goal, University, OTC, TLR5, Review, Entolimod, Therapy, Learning, Association, Canadian Aviation Regulations, Research, Patent, Securities Act of 1933, Securities Exchange Act of 1934, Toxicity, SPAC, Acute radiation syndrome, Forward-looking statement, Humanitarian use licenses, Technology, Ovarian cancer, National, CAR, Acquisition, Laboratory, Security (finance), CEO, Vaccine, Pharmaceutical industry, Immunology, Chemistry

WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development are pre-clinical programs targeting breast cancer and ovarian cancer. Terms of the deal were not disclosed.

Key Points: 
  • Among the initial cancer indications under development are pre-clinical programs targeting breast cancer and ovarian cancer.
  • Per the option agreement, Coeptis paid the University of Pittsburgh a non-refundable fee for the exclusive option to license the patent rights to each of the three technologies.
  • Coeptis has until October 29, 2022, to exercise the options and pay the specified exercise considerations.
  • The option agreement may be extended an additional six months, subject to the agreement of both parties.

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Retrieved on: 
Friday, May 13, 2022
Cancer, Immunoglobulin Y, Company, Autoimmunity, Cleveland BioLabs, TLR, Exercise, Infection, Patient, Homeostasis, Cleveland, Antibody, Coronavirus, TLR5, COVID-19, Fibromyalgia, Research, Entolimod, TLR4, Partnership, Virus, Multiple sclerosis, Budget, Union, Risk, Pancreatic cancer, Science, GI, SEC, Growth, TLR9, GLOBE, Fine chemical, Bookkeeping, Vaccine

The strategic partnership with Lay Sciences has the potential to produce near term revenue, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.

Key Points: 
  • The strategic partnership with Lay Sciences has the potential to produce near term revenue, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.
  • Statera also receives the right to license and commercialize current and future products for other indications.
  • Using patent pending and proprietary technologies owned by Lay Sciences or licensed from its partnering companies, ReaGene Biosciences Pvt.
  • Ltd., Lay Sciences is dedicated to developing and providing innovative products and devices focused on treating and preventing diseases of the GI tract.

Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone

Retrieved on: 
Wednesday, April 27, 2022
Antibody, TLR5, Budget, Virus, CEO, Cancer, Patient, GLOBE, Homeostasis, UCSF, Union, Therapy, Asthma, HIV, LDN, Pancreatic cancer, COVID-19, State university system, Cleveland BioLabs, TLR, Growth, Risk, Company, Achievement, Autoimmunity, University of Chicago, Exercise, Marketing, Cleveland, Entolimod, Drug development, Research, TLR4, State University of New York, Coronavirus, Immunity (medical), Fibromyalgia, University, SEC, Immunotherapy, TLR9, Multiple sclerosis, Pharmaceutical industry, Vaccine, Naltrexone

The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.

Key Points: 
  • The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.
  • Under the anticipated terms of the agreement, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics.
  • Stateras naltrexone assets will be a great addition to our immune-modulation products and immunotherapy technologies, said Kevin Phelps, CEO, Immune Therapeutics.
  • The companys technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).

Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing

Retrieved on: 
Friday, April 22, 2022
Letter, Multiple sclerosis, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Audit committee, Risk, Research, GLOBE, Patient, TLR5, Mission statement, Antibody, TLR9, Entolimod, Annual report, Compliance, Board of directors, Company, Board, LLP, Form 10-K, Pancreatic cancer, Growth, TLR4, SEC, Coronavirus, Cleveland BioLabs, Exercise, TLR, Virus, Time, Homeostasis, The Annual Report, Fibromyalgia, Calendar, Autoimmunity, Budget, TSC, Union, Cancer, Attention, Cleveland, Online gambling, Risk management, Audit, Management, Nasdaq

There is no assurance, however, that the Companys plan will be accepted by Nasdaq nor that the Company will successfully implement its plan.

Key Points: 
  • There is no assurance, however, that the Companys plan will be accepted by Nasdaq nor that the Company will successfully implement its plan.
  • Further on April 13, 2022, the Company announced it was no longer in compliance with several of the Nasdaq Stock Markets rules.
  • First, under Nasdaq Listing Rule 5605(b)(1), a majority of the directors on the Board must be independent directors, as defined under the Nasdaq rules.
  • If Nasdaq accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from April 4, 2022, the date of Nasdaqs letter to the Company regarding this noncompliance matter, to evidence compliance.

Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

Retrieved on: 
Wednesday, April 13, 2022
Fibromyalgia, TLR9, Multiple sclerosis, COVID-19, Risk, Research, Pancreatic cancer, Autoimmunity, GLOBE, OTC, Patient, Budget, TLR5, Growth, Company, TLR4, SEC, Coronavirus, Antibody, Union, Cleveland, Cleveland BioLabs, Cancer, Exercise, TLR, Virus, Therapy, Homeostasis, Pharmaceutical industry, Entolimod

Coeptis commitment to cancer therapies makes it a natural choice for the further development of Entolimod, which has demonstrated potential in multiple preclinical disease models, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.

Key Points: 
  • Coeptis commitment to cancer therapies makes it a natural choice for the further development of Entolimod, which has demonstrated potential in multiple preclinical disease models, said Michael K. Handley, President and Chief Executive Officer of Statera Biopharma.
  • Under the terms of the definitive agreement, Statera will receive a $6 million upfront payment and revenue-based milestone payments from Coeptis in exchange for Stateras rights to any product containing Entolimod as an active ingredient and all other related TLR5 agonists.
  • We are excited to undertake this strategic investment to help develop innovative therapeutics that offer improved patient outcomes, said Dave Mehalick, Chairman, President and Chief Executive Officer of Coeptis.
  • Statera has clinicalprograms for Crohns disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma

Retrieved on: 
Wednesday, April 13, 2022
Entolimod, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, Acute radiation syndrome, Anemia, OTC, Patient, Goal, TLR5, Karolinska Institute, Review, Technology, Hematology, Neutropenia, Nasdaq, Company, NF-κB, Apoptosis, Radiation exposure, Forward-looking statement, Reactive oxygen species, Therapy, Cancer, Pharmaceutical industry

WEXFORD, Pa. , April 13, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that the Company has entered into a strategic agreement with Statera Biopharma, Inc. (Nasdaq: STAB) that gives Coeptis the right to acquire Statera's toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency. Coeptis and Statera have agreed to an exclusivity period through the date that is 30 days following the date on which the first draft of the definitive agreement is available to review by both parties. 

Key Points: 
  • The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
  • Entolimod is Statera's most advanced TLR5 agonist technology and is currently in development to treat acute radiation syndrome.
  • Coeptis was founded in 2017 and is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/ .
  • Additional factors are discussed in our filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov .

Statera Biopharma, Inc. Files Form 12b-25

Retrieved on: 
Thursday, March 31, 2022
Budget, Company, The Annual Report, Entolimod, Virus, Cancer, Hematology, Multiple sclerosis, Mission statement, TLR5, Autoimmunity, Fibromyalgia, TLR, SEC, Webcast, Homeostasis, TLR4, Calendar, U.S. Securities and Exchange Commission, Nasdaq, COVID-19, GLOBE, Annual report, TLR9, Pancreatic cancer, Patient, Annual, Antibody, Audit, Pharmaceutical industry

Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in the Annual Report.

Key Points: 
  • Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in the Annual Report.
  • As a result of todays announcement, the Company postponed its conference call and webcast to discuss its financial results for full year 2021.
  • Statera Biopharma has a large platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532.
  • Statera Biopharma has clinical programs for Crohns disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Retrieved on: 
Monday, March 28, 2022
Budget, Company, Virus, Entolimod, Cancer, Hematology, Multiple sclerosis, TLR5, Autoimmunity, Fibromyalgia, TLR, SEC, Webcast, Homeostasis, TLR4, COVID-19, TLR9, Pancreatic cancer, Patient, Antibody, Vaccine

FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Statera Biopharma has a large platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532.
  • TLRs are a class of protein that plays a key role in the innate immune system.
  • Statera Biopharma has clinical programs for Crohns disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.
  • The Companys actual future results may differ materially from those discussed here for various reasons.